A hamster antimouse CD3 monoclonal antibody (MoAb) opened the way t o experimental studies on the suppression of allograft rejection and cytokine-related morbidity after treatment with antibodies modulating the CD3/T-cell receptor complex (CD3/TCR). Because earlier attempts t o suppress graft-versus-host disease (GVHD) in patients by in vitro treatment of donor marrow with anti-CD3 MoAb had remained inconclusive, we used a rat lgG2b antimouse CD3 MoAb (17A2) with fewer side effects t o analyze suppression of GVHD in the mouse model. Detailed phenotyping of blood, spleen, and lymphnode T cells after the injection of 400 pg 17A2 in C57BL/6 mice showed 60% CD3 downmodulation and 50% T-cell depletion for spleen cells. Injection of these spleen cells, together with bone marrow cells, in fully mismatched preirradiated CBA mice delayed GVHD by only 6 days. Ex vivo treatment of donor cells with 17A2 was not effective. In contrast, conditioning of marrow recipients with HE ANTI-CD3 monoclonal antibody (MoAb) T is the immunosuppressive anti-T-cell MoAb that has been studied in patients most e~tensively.4,~ CD3 on T cells is in close contact with the T-cell receptor (TCR) heterodimer. The CD3/TCR complex plays an important role in signal transduction after binding to appropriately presented antigen. However, binding of anti-CD3 MoAb induces TCR signaling in an antigen-independent way.
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In the field of clinical bone marrow transplantation, early studies reported reduction of graft-versus-host disease (GVHD) after in vitro treatment of the donor marrow with anti-CD3 MOA^.^,^ Nevertheless, cases with severely acute GVHD were observed even when heterologous complement had been added to the antibody. 8 This seemed surprizing because OKT3 depleted circulating T lymphocytes when injected in patients with GVHD.9 On the other hand, OKT3-induced reversal of kidney graft rejection was also seen in patients without clearly depressed T-lymphocyte counts, suggesting immunosuppression after dysfunction, sequestration of T cells, or modulation of the CD3/ TCR complexlOJ1 rather than pure T-cell elimination. The generation of a hamster antimouse-CD3 MoAb (145-2C11) was, therefore, an important step towards analyzing the in vivo consequences of antibody binding to CD3. [12] [13] [14] [15] [16] We have long been interested in analyzing antibodyinduced prevention of GVHD in mice, having studied mouse and rat isotypes of T-cell-depleting MoAb. Only strongly T-cell-depleting ( > 95%) rat IgG2b or mouse IgG2a anti-Thy-1 MoAb prevented GVHD in fully mismatched mice, no matter whether used in vitro" or applied to the marrow donorla or re~ipient.l~-~' Therefore, we were interested in studying the suppression of GVHD with modulating anti-CD3 MoAb whose suppression of skin graft rejection was accompanied by a lower degree of T-cell dep1eti0n.I~ We did not use the hamster anti-CD3 145-2C11 MoAb because of its well-documented cytokine-related morbidity.16 It caused significant mortality even in our control mice grafted with syngeneic bone marrow. Fortua single injection of 17A2 delayed 50% GVHD mortality by 100 days and prevented GVHD altogether after prolonged treatment, with survivors showing complete chimerism and specific transplantation tolerance. This difference in antibody effect contrasts with earlier experiences with nonmodulating but more strongly T-cell-depleting MoAbs of the same isotype, which prevent GVHD no matter whether applied in vitro or injected into donor or recipient mice. Our data indicate that CD3/TCR reexpression in marrow recipients with no circulating 17A2 is the reason why ex vivo donor cell treatment with anti-CD3 MoAb is comparatively ineffective. Our data, which allow separate evaluation of cell-depleting and cell-modulating antibody activity, help t o explain previous clinical failure t o suppress GVHD and provide evidence in favor of conditioning the marrow recipient with anti-CD3 MoAb as a therapeutic alternative. 0 1992 by The American Society of Hematology.
nately, the rat antimouse-CD3 17A2, which cross-competes with the hamster 145-2C11 anti-CD3 MoAb on the C D~E chain and similarly stimulates interleukin-2 (IL-2) production22 and proliferation of T cells, was better tolerated. We measured an approximately 15% weight loss 3 days postinjection compared with 30% weight loss with the hamster antibody. However, delay of skin graft rejection was comparable. 17A2 is an IgG2b antibody of the isotype, which was shown to be the most immunosuppressive of the T-celldepleting rat MoAb.17,23,24 This allowed us to more directly compare 17A2 with primarily T-cell-depleting anti-Thy-1 MoAb. We found that anti-CD3 MoAb 17A2 in fact suppresses GVHD, even in fully allogeneic H2 mismatched mice, but only when injected and circulating in the marrow recipient at the time of bone marrow transplantation. Treatment of marrow donors or marrow donor cells was clearly less effective, probably because mature T cells in the marrow inocculum recovered their CD3/TCR and GVHDinducing potential in marrow recipients when no 17A2 was circulating. In connection with earlier clinical failures, our conclusions help to explain why maximal suppression of GVHD by CD3 modulating MoAb cannot be expected when the latter are used for ex vivo T-cell treatment rather than for conditioning of the marrow recipient. 
MATERIALS AND METHODS
Animals. C57BL/6 mice originally obtained from the Jackson Laboratory (Bar Harbor, ME) were raised and maintained in our breeding facilities. CBA and (C57BL/6 x CBA)Fl mice were bred from stock in our own laboratory. Three-month-old female animals were used as bone marrow recipients.
Flow cytometry was performed as described p r e v i o~s l y ,~~,~~ using fluorescein (FITC)-or phycoerythrin (PE)-conjugated anti-L3T4 (Becton Dickinson, Heidelberg, Germany), anti-Lyt2 (Serva, Heidelberg, Germany), anti-B220 (Medac, Hamburg, Germany), anti-Thy-1.2 (Medac), MoAb, or polyclonal mouse F(ab)z-antirat IgG (Dianova, Hamburg, Germany). 17A2 (rat2b-antimouse-CD3) was donated by Dr R. MacDonald (Ludwig Institute for Cancer Research, Lausanne, Switzerland),22 anti-IL-2R (TIB 222; ATCC) and anti-NK-1.1 (HB-191; ATCC) were purified from culture supernatant using protein G chromatography. Ascitic fluids of anti-H2Kk and anti-H2Db MoAb (Camon, Wiesbaden, Germany) were purified as described elsewhere.26 MoAb 17A2, anti-H2Kk, anti-IL-2R, and anti-NK-1.1 were FITC-labeled as described elsewherez7; MoAb anti-H2Db was biotinilated as described p r e v i o~s l y .~~
In vivo modulation of CD3 and T-cell depletion after 17A2 treatment. C57BL/6 mice were injected intravenously (IV) with a single 400 (20 mg/kg), 100, or 25 Fg dose of purified anti-CD3 (17A2) MoAb. Heparinized blood, spleen, and lymphnodes (axillary, inguinal, mesenteric) from three mice were pooled 1,3,7, and 10 days after injection, a cell suspension was prepared, and leukocytes were counted. One million leukocytes were doublelabeled using saturating concentrations of anti-L3T4(PE)/anti-
anti-B220(PE) and, after standard NHdCI lysis of erythrocytes, were processed on FACScan (Becton Dickinson). The quantitative fluorescence measurements of CD3 expression were performed directly using FITC-labeled 17A2, or indirectly using purified 17A2 and mouse F(ab')2 antirat IgG (FITC), as described p r e v i o~s l y .~~ FCSC Microbead Standards (Becton Dickinson) were used as fluorescence standards.
Serum concentration of 17A2 (anti-CD3) MoAb and anti-I7A2 antibodies afier in vivo treatment. Concentration of 17A2 (rat IgG2b) was determined in enzyme-linked immunosorbent assay (ELISA), using mouse-antirat IgG (Dianova) as the capture and the same peroxidase-labeled antibodies as the indicator. Sera from treated mice or purified 17.42 as the concentration standard were titrated twofold and the concentration of rat Ig in serum was calculated. To determine anti-17A2 antibodies, ELISA microtiter plates (Greiner, Niirtingen, Germany) were coated with purified 17A2. Sera from 17A2-treated mice or affinity-purified polyclonal mouse-antirat IgG (Dianova) as the concentration standard were titrated twofold and indicated with peroxidase-labeled ratantimouse IgG (Dianova). The concentration of anti-17A2 antibodies was calculated from mouse-antirat IgG standard curves.
Bone marrow transplantation and X-radiation were performed as described in detail pre~iously.'~ Briefly, in vivo treatment was as follows: groups of six irradiated (8.5 Gy) CBA (H-2k) or (C57BL/ 6 X CBA)Fl recipient mice were injected IV with a given concentration of purified anti-CD3 (17.42) MoAb. A mixture of 5 x lo7 spleen and 2 x lo7 bone marrow cells from C57BL/6 (H-2b) donors was injected 4 hours later. Alternatively, prospective C57BL/6 donors were injected with 17A2 or control antibody of the same rat IgG2b isotype, but irrelevant specificity (anti-DNP); bone marrow and spleen cells were removed 3 days later and injected into recipient mice at the same proportion as above. For in vitro treatment, a mixture of 35 x lo7 spleen and 14 x lo7 bone marrow Antibodies and @ow cytometry.
cells from C57BL/6 mice was incubated in 1 mL minimal essential medium (MEM; Biochrom, Berlin, Germany) with 5 x saturating concentration of purified 17A2 MoAb for 30 minutes at room temperature. Afterwards 150 ILL of a mixture of 2 x lo7 bone marrow and 5 X lo7 spleen cells per mouse was injected into lethally irradiated CBA or (C57BL/6 x CBA)Fl recipient mice. Statistical evaluation of survival curves was performed using the logrank meth0d.2~
Heparinized blood was collected from the tails of mice who received Test for chimerism and specific transplantation tolerance. bone marrow transplants and the cells were double-labeled with anti-H2k FITC and biotinylated anti-H2b MoAb. After probing with avidin-PE and FACScan processing, live lymphoid cells were evaluated and compared with cells of untreated control mice. Bone marrow-reconstituted mice were tested for specific tolerance 50 days after transplantation. They were grafted with marrow donortype (C57BL/6) and third-party (Balb/c) tail skin grafts, both placed on the lateral thoracic wall. Dressings were removed on day 12 and grafts were inspected every day for signs of rejection.
RESULTS
Suppression of GVHD by anti-CD3 MoAb (17A2) was tested after antibody treatment of marrow donors or recipients or of donor cells in vitro. Changes in T-cell depletion and modulation after treatment of C57BL/6 donor mice were measured by detailed immunophenotyping.
Single injections of 400 pg 17A2 in C57BL/6 mice produced a reduction of T cells, which were measured on day 1,3,7, and 10 postinjection in blood, spleen, and lymphnode cells (Fig 1) . Cell depletion was most pronounced in blood (80%) on day 1 and approximately 50% T-cell reduction was measured in spleen and lymphnode cell suspension pooled from axillary, inguinal, and mesenteric lymphnodes. Splenic T cells had reached a 50% reduction by day 3, at which time peripheral blood lymphocytes (PBL) T-cell counts had already increased, although CD3 was still modulated (see below). T-cell counts on days 7 and 10 had stabilized at about half the normal values. Virtually the same pattern was observed after a single injection of 100 pg 17A2. Markedly diminished T-cell depletion and modulation were noted in blood, lymph nodes, and spleen after the injection of 25 pg 17A2 (data not shown).
Fifty days after a single injection of 400 pg of 17A2, CD4+ cells had reached normal values; CD8+ cells recovered slowly, reaching some 65% to 75% of untreated controls (data not shown). For personal use only. on November 11, 2017. by guest www.bloodjournal.org From transplantation, all splenic CD4+ and CD8+ cells were saturated with circulating 17A2; CD3 downmodulation can be assumed because the concentration of bound 17A2 was 60% lower than for untreated controls. The diminished antigen density was still seen, even after 17A2 had disappeared from serum on days 7 and 10 after treatment (Figs 1  and 2 ). Complete modulation must have occurred on PBL because approximately 40% to 50% of PBL on day 3 post injection of 100 or 400 pg 17A2 did not stain with directly labeled 17A2 nor with FITC-labeled antirat Ig secondary antibodies. They had lost their CD3 antigen completely, at least below the threshold of sensitivity of the FACS. During in vivo treatment with 17A2, we did not find increased expression of IL-2R on T cells as reported for 145-2C11.14 Transplantation of 5 x lo7 spleen cells together with 2 x lo7 bone marrow cells to irradiated, minor and major MHC class I and IImismatched CBA mice induced acute mortality, which was only slightly delayed if donor or donor cells were pretreated with anti-CD3 MoAb (Fig 3) . In contrast, the injection of 400 or 200 pg antibody in marrow recipients 20 hours after irradiation and 4 hours before transplantation suppressed GVHD mortality by about 50% on day 100 posttransplantation and 20% to 40% on day 200. In one experiment, permanent survival of 80% of chimeras was observed after single injection of 200 pg 17A2 (Fig 3, experiment 2 ). Prolonging antibody treatment by further injections of 200 pg on days 3,6, and 9 after transplantation led to long-term survivors with 90% to 97% chimerism on days 50 and 100. Compared with untreated controls, GVHD suppression in 17A2-treated recipients was statistically significant (P < .05) for all above described treatments. The differences in survival resulting from dose of 17A2 or prolonging of treatment were not statistically significant (Fig 3) . Chimeras showed long-lasting changes in blood T-cell frequency (Table 1) . Even 50 days after the last injection of 17A2, the frequency of CD4+ cells was reduced to about 50% and CD8+ cells were reduced to 10% of untreated controls. On day 200 posttransplantation, recovery of blood CD8+ cells improved to 50% of untreated controls; percentage of splenic CD4+ cells had reached control values and splenic CD8+ cells were reduced by 65%. C57BL/6-into-CBA Effect of anti-CD3 MoAb on GVHD.
chimeras (chimerism was proved on days 30, 50, and 100 posttransplantation and regularly found to be greater than 90%), grafted 50 days after bone marrow transplantation with donor C57BL/6 or third party (Balb/c) skin, accepted donor skin and promptly rejected third-party skin. Besides changes in the frequency of CD4+ and CD8+ lymphocytes, we regularly observed an increase in donor NK 1.1 cells (Table 1) ; however, this was not predictive for GVHD in our mice. The formation of antiantibodies against 17A2 was negligible in these experiments (Table 1) . We repeated the GVHD experiments with C57BL/6 donors in semiallogeneic (CBL/6 x CBA)Fl recipient mice. This donor-recipient incompatibility is notoriously easy to overcome. Even the injection of normal rabbit Ig causes some delay of GVHD. Again, conditioning of recipient mice with 17A2 was most effective. Pretreatment of donors or donor cells ex vivo showed a clearly delayed, but 100% mortality (Table 2) . Taking advantage of the sensitivity of this mouse model, we titrated the spleen cells from donors pretreated with an MoAb of irrelevant specificity in the *Donors were injected IV with 400 Fg 17A2; bone marrow/spleen cells were prepared 3 days later and transplanted.
117A2 injected IV at indicated dose 4 hours before transplantation.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From ANTI-CD3 SUPPRESSES GVHD 2665 semiallogeneic GVHD model. The cell-dose-dependent delay of GVHD was correlated to a delay of GVHD after the transplantation of 5 x lo7 spleen cells from donors who had been pretreated with 17A2 (Fig 4) . Because 17A2 induced 50% T-cell depletion in the spleen (see above), we expected a delay of GVHD mortality corresponding to the delay after the transfer of 2.5 x lo7 spleen cells of our control mice. However, anti-CD3 MoAb delayed GVHD significantly more (P = . 009, Fig 4) . These results support the conclusion that immunosuppression by 17A2 cannot be explained by its T-cell depletion alone. The CD3/TCR modulation must at least have played a role.
DISCUSSION
The present observations concern an interrelationship between antibody action and type of conditioning for suppression of GVHD. Extending experimental studies on antimouse CD3 MoAb to the suppression of GVHD, we show in the mouse GVHD model that this modulating antibody is relatively ineffective in ex vivo T-cell treatment, but successful when used for conditioning bone marrow recipients. This difference in immunosuppressive effect contrasts with that of primarily T-cell-depleting MoAbs, which are equally effective in both types of treatment.17J9 Whereas purging with anti-T-cell antibodies depends on their Fc-parts?O an important anti-CD3 antibody effector function extends to its variable T-cell-binding part that causes downmodulation of the CD3/TCR complex. F(ab')2 fragments of anti-CD3 MoAb have thus been shown to conserve much of its immunosuppressive activity by prolonging survival of skin al10grafts.l~ In the present study, pretreating of C57BL/6 donor mice with 17A2 resulted in dose-dependent T-cell elimination and downmodulation of the CD3 /TCR receptor complex, which were most pronounced in blood and spleen cells. We transplanted spleen and bone marrow cells of mice injected with up to 400 kg 17A2 3 days earlier. At this time, splenic T cells had decreased to about 50%. They also showed a reduction in CD3 expression of about 60%, as measured by binding 17A2 (Fig 1) . The spleen T cells, despite their reduced number and TCR downmodulation, hardly delayed acute GVHD mortality at all (Fig 3) . In vitro tests for T-cell function, in which spleen cells from mice injected with anti-CD3 MoAb 145-2C11 and tested for generation of cytotoxic T-lymphocyte-mediated lysis (CTL) of complete MHC-disparate target cells, showed no CTL activity for at least 5 weeks ~0sttreatment.I~ Clearly, in vivo conditions for GVHD-inducing T cells must be quite different. Other factors, eg, preirradiation of marrow recipients, cytokines, or upregulation of target antigens, may have contributed to in vivo T-cell stimulation and early recovery of graft-versushost response. On the other hand, successful marrowrecipient conditioning-not only in the notoriously 'easier' parent-to-F1 system, but also in fully mismatched CBA mice-proved the potential anti-GVHD effectiveness of 17A2. It underscores the importance of circulating anti-CD3 MoAb for maintaining inhibition and dysfunction of donor cell TCR in the early stages after transplantation. It is conceivable that T-cell-depleting antibodies like antiThy-1 MoAb (and we found the same for antimouse CD4/CD8 antibody pairs [data not shown]) are equally effective in donor, donor-cell, or recipient treatment as long or avoided by i~o t y p e -m a t c h i n g ,~~ p e n t o~p h i l l i n e ,~~ by antibodies t o tumor necrosis f a~t o r ,~~,~~ or by anti-CD3 F(ab'), fragment^.^^.^^
